Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Default user image.

Katarina Sjögreen Gleisner

Professor

Default user image.

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

Författare

  • Katarina Sjögreen Gleisner
  • Nicolas Chouin
  • Pablo Minguez Gabina
  • Francesco Cicone
  • Silvano Gnesin
  • Caroline Stokke
  • Mark Konijnenberg
  • Marta Cremonesi
  • Frederik A. Verburg
  • Peter Bernhardt
  • Uta Eberlein
  • Jonathan Gear
Visa allt

Summary, in English

The purpose of the EANM Dosimetry Committee is to provide recommendations and guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals labelled with lutetium-177 (177Lu) are increasingly used for therapeutic applications, in particular for the treatment of metastatic neuroendocrine tumours using ligands for somatostatin receptors and prostate adenocarcinoma with small-molecule PSMA-targeting ligands. This paper provides an overview of reported dosimetry data for these therapies and summarises current knowledge about radiation-induced side effects on normal tissues and dose-effect relationships for tumours. Dosimetry methods and data are summarised for kidneys, bone marrow, salivary glands, lacrimal glands, pituitary glands, tumours, and the skin in case of radiopharmaceutical extravasation. Where applicable, taking into account the present status of the field and recent evidence in the literature, guidance is provided. The purpose of these recommendations is to encourage the practice of patient-specific dosimetry in therapy with 177Lu-labelled compounds. The proposed methods should be within the scope of centres offering therapy with 177Lu-labelled ligands for somatostatin receptors or small-molecule PSMA.

Avdelning/ar

  • Medicinsk strålningsfysik, Lund
  • Nuclear Medicine Physics

Publiceringsår

2022-05

Språk

Engelska

Sidor

1778-1809

Publikation/Tidskrift/Serie

European Journal of Nuclear Medicine and Molecular Imaging

Volym

49

Issue

6

Dokumenttyp

Artikel i tidskrift

Förlag

Springer

Ämne

  • Radiology, Nuclear Medicine and Medical Imaging

Nyckelord

  • Dosimetry
  • Lutetium-177
  • Neuroendocrine
  • Prostate adenocarcinoma
  • PSMA-targeting ligands
  • Somatostatin-receptor ligands

Aktiv

Published

Forskningsgrupp

  • Nuclear Medicine Physics

ISBN/ISSN/Övrigt

  • ISSN: 1619-7070